Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Bafilomycin A1 (HB1125)
Description:Highly potent, selective V-ATPase inhibitor. Autophagy inhibitor.
Purity:>98%
Ivermectin (IVM) (HB1958)
Description:α7 nicotinic acetylcholine receptor positive allosteric modulator. Activates GluCI/GlyCI chemogenetic channels. Shows antiviral activity.
Purity:>95%
Monensin sodium salt (HB4882)
Description:Protein transport inhibitor. Commonly used in cytokine staining.
Purity:>98%
Mycophenolic acid (HB3987)
Description:Inosine monophosphatase dehydrogenase inhibitor
Purity:>98%